Plasmodium Falciparum Malaria Clinical Trial
Official title:
SP Resistance Markers and Falciparum Malaria Transmission
The purpose of this study is to study resistance to current malaria treatments and affordable alternatives for uncomplicated malaria. Resistance occurs in areas where these treatments are used frequently. This study may help prevent future resistance. About 150 residents in Buenaventura, Colombia will participate. They will have uncomplicated malaria and they will be followed for 28 days after treatment. Physical exams and blood draws are included in study visits.
Drug-resistant Plasmodium falciparum is a major threat to global public health and new strategies are needed to deter spread of resistance to available and forthcoming antimalarial drugs. This study seeks to contribute to understanding the molecular basis of spread of drug resistance in a setting with low level of sulfadoxine-pyrimethamine (SP) treatment failure. The objectives of this study are to compare the prevalence of dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) point mutations associated with SP resistance before and after SP treatment of uncomplicated Plasmodium falciparum malaria episodes and to measure parasite infectivity to Anopheles mosquitoes of post-treatment gametocytes with and without DHFR and DHPR mutations. Patients with uncomplicated falciparum malaria will receive a standard SP regimen and will be closely followed for 28 days. This study will add new knowledge of the understanding of ways in which resistance is spread and is expected to provide a sound basis for the future clinical evaluation of antimalarial drug combinations designed to prevent transmission of drug-resistance malaria. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04577066 -
Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites.
|
Phase 1/Phase 2 | |
| Completed |
NCT01883609 -
A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S
|
Phase 1/Phase 2 | |
| Completed |
NCT00593398 -
Malarial Immunity in Pregnant Cameroonian Women
|
||
| Completed |
NCT01659281 -
Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand
|
N/A | |
| Completed |
NCT00074841 -
Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04416945 -
Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic
|
N/A | |
| Completed |
NCT00314899 -
Fetal Immunity to Falciparum Malaria
|
||
| Completed |
NCT02867059 -
SJ733 Induced Blood Stage Malaria Challenge Study
|
Phase 1 | |
| Completed |
NCT00701961 -
Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy
|
Phase 2/Phase 3 | |
| Completed |
NCT00338520 -
Hyperphenylalaninemia in Cerebral Malaria
|
N/A | |
| Completed |
NCT00707200 -
The Cytoadherence in Pediatric Malaria (CPM) Study
|
N/A | |
| Completed |
NCT00393757 -
Malaria Transmission and Immunity in Highland Kenya
|
||
| Completed |
NCT03783299 -
Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic
|
Phase 4 | |
| Completed |
NCT02614404 -
Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria
|
Phase 1 | |
| Completed |
NCT00358332 -
Phase I Pediatric FMP2.1/AS02A Trial in Mali
|
Phase 1 | |
| Completed |
NCT00730782 -
Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers
|
Phase 1 | |
| Completed |
NCT00349713 -
FMP2.1 Trial in Bandiagara, Mali
|
Phase 1 | |
| Recruiting |
NCT05052502 -
Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand
|
N/A | |
| Completed |
NCT04093765 -
Mass Screening and Treatment for Reduction of Falciparum Malaria
|
N/A | |
| Completed |
NCT03764527 -
Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar
|
Phase 4 |